Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995391 · ClinicalTrials.gov registry record · NA
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
A NA study of Atrial Fibrillation (AF), sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT06995391: Recruiting NA study of Atrial Fibrillation (AF), sponsored by University of California, San Francisco.
NCT06995391 is a NA study of Atrial Fibrillation (AF) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 1,000 participants, above the 661-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (51% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06995391, a NA study of Atrial Fibrillation (AF), is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Per the 2021 National Survey on Drug Use and Health administered by the U.S. Department of Health and Human Services, 85% of all American adults consume alcohol. Atrial fibrillation (AF) is the most common arrhythmia, affecting more than 10 million individuals in U.S., comprising 4.5% of the adult population. Although alcohol abstinence clearly reduces AF in heavy drinkers, observational data comparing the health effects of limited consumption versus abstention are conflicting. The Mediterranean diet is one of the few that has demonstrated clear cardiovascular benefits in a randomized study-this diet allows for the consumption of red wine (or high polyphenol/ low alcohol alcohol), generally not more than one drink in 24 hours, with meals, avoiding spirits and binge drinking. The effect of the "Mediterranean drinking pattern" on AF risk compared to alcohol abstinence remains unknown. This single center, randomized, controlled trial aims to compare the effects of a digital health intervention to encourage durable alcohol abstinence versus allowing guideline-adherent moderate alcohol consumption on AF severity. The knowledge gained from this study may be used to determine optimal thresholds for alcohol use among AF patients.
Primary Outcome
The primary outcome will be change in atrial fibrillation severity at one year, defined by a change in the Atrial Fibrillation Effect on Quality-of-Life Questionnaire (AFEQT) score from baseline to one year associated with alcohol abstinence. Based on previously reported values of clinically relevant change in AFEQT score (PMID 31092022), the investigators estimate the change in mean AFEQT score from baseline to 1 year to be 5.4±17.03 in the Alcohol Abstinence group and 0.2±15.17 in the Contemp
Conditions Studied
Interventions
- BEHAVIORAL Contemporary Guideline-Adherence
- BEHAVIORAL Alcohol Abstinence
Study Locations (1)
California
- UCSF Medical Center at Parnassus - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-04-20 |
| Est. Completion | 2030-03-01 |
| Phase | NA |
What NCT06995391 shows while recruiting
NCT06995391 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 661-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (51% higher).
The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 2 interventions - of which Contemporary Guideline-Adherence is the first listed.
NCT06995391 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06995391 about?
NCT06995391 is a clinical study titled "Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity". Per the 2021 National Survey on Drug Use and Health administered by the U.S. Department of Health and Human Services, 85% of all American adults consume alcohol. Atrial fibrillation (AF) is the most common arrhythmia, affecting more than 10 million individuals in U.S., comprising 4.5% of the adult p...
What is the current status of trial NCT06995391?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-04-20. Estimated completion is 2030-03-01.
What conditions does trial NCT06995391 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF).
What interventions are being tested in trial NCT06995391?
The interventions under investigation include: Contemporary Guideline-Adherence (BEHAVIORAL), Alcohol Abstinence (BEHAVIORAL).
Who is sponsoring clinical trial NCT06995391?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995391 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06995391's enrollment target sits among peer trials
1,000 5th of 17 higher than 12 of 17 other Atrial Fibrillation (AF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation (AF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
RECRUITING · NA
-
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
RECRUITING · NA
-
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
RECRUITING · NA
-
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
RECRUITING · NA
-
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI